Pacer Advisors, Inc. United Therapeutics Corp Transaction History

Pacer Advisors, Inc.

  • $41.8 Billion
  • Q3 2024

A detailed history of Pacer Advisors, Inc. transactions in United Therapeutics Corp stock. As of the latest transaction made, Pacer Advisors, Inc. holds 566,703 shares of UTHR stock, worth $204 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
566,703
Previous 561,834 0.87%
Holding current value
$204 Million
Previous $179 Million 13.47%
% of portfolio
0.49%
Previous 0.46%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$311.04 - $363.55 $1.51 Million - $1.77 Million
4,869 Added 0.87%
566,703 $203 Million
Q2 2024

Aug 13, 2024
BUY
$228.26 - $319.04 $21.1 Million - $29.4 Million
92,240 Added 19.64%
561,834 $179 Million
Q1 2024

May 10, 2024
BUY
$210.76 - $249.51 $33 Million - $39.1 Million
156,795 Added 50.13%
469,594 $108 Million
Q4 2023

Jan 16, 2024
BUY
$214.88 - $256.94 $14.6 Million - $17.4 Million
67,738 Added 27.64%
312,799 $68.8 Million
Q3 2023

Nov 13, 2023
BUY
$211.82 - $248.24 $6.7 Million - $7.85 Million
31,633 Added 14.82%
245,061 $55.4 Million
Q2 2023

Jul 12, 2023
BUY
$205.19 - $232.99 $8.48 Million - $9.63 Million
41,327 Added 24.01%
213,428 $47.1 Million
Q1 2023

May 02, 2023
BUY
$212.99 - $276.17 $34.5 Million - $44.7 Million
161,777 Added 1567.0%
172,101 $38.5 Million
Q4 2022

Feb 06, 2023
SELL
$205.95 - $280.43 $15.2 Million - $20.7 Million
-73,681 Reduced 87.71%
10,324 $2.87 Million
Q3 2022

Oct 18, 2022
SELL
$203.3 - $244.17 $3.72 Million - $4.47 Million
-18,308 Reduced 17.89%
84,005 $17.6 Million
Q2 2022

Aug 12, 2022
BUY
$174.81 - $241.14 $8.65 Million - $11.9 Million
49,493 Added 93.7%
102,313 $24.1 Million
Q1 2022

Apr 05, 2022
BUY
$166.16 - $213.96 $8 Million - $10.3 Million
48,176 Added 1037.38%
52,820 $9.48 Million
Q4 2021

Feb 03, 2022
SELL
$184.32 - $216.08 $2.41 Million - $2.83 Million
-13,092 Reduced 73.82%
4,644 $1 Million
Q3 2021

Oct 15, 2021
BUY
$179.86 - $214.88 $185,435 - $221,541
1,031 Added 6.17%
17,736 $3.27 Million
Q2 2021

Jul 21, 2021
BUY
$170.47 - $211.93 $563,573 - $700,640
3,306 Added 24.67%
16,705 $3 Million
Q1 2021

Apr 05, 2021
SELL
$153.94 - $174.85 $111,452 - $126,591
-724 Reduced 5.13%
13,399 $2.24 Million
Q4 2020

Jan 20, 2021
SELL
$101.87 - $151.79 $723,990 - $1.08 Million
-7,107 Reduced 33.48%
14,123 $2.14 Million
Q3 2020

Oct 19, 2020
BUY
$99.9 - $121.13 $1.28 Million - $1.55 Million
12,826 Added 152.62%
21,230 $2.14 Million
Q2 2020

Jul 29, 2020
BUY
$92.74 - $125.82 $779,386 - $1.06 Million
8,404 New
8,404 $1.02 Million
Q1 2020

Apr 23, 2020
SELL
$79.39 - $115.35 $1.16 Million - $1.69 Million
-14,643 Closed
0 $0
Q4 2019

Feb 10, 2020
SELL
$78.31 - $95.34 $87,393 - $106,399
-1,116 Reduced 7.08%
14,643 $1.29 Million
Q3 2019

Oct 10, 2019
BUY
$74.85 - $85.99 $1.18 Million - $1.36 Million
15,759 New
15,759 $1.26 Million
Q1 2019

Apr 10, 2019
SELL
$107.15 - $126.84 $539,393 - $638,512
-5,034 Closed
0 $0
Q4 2018

Feb 13, 2019
SELL
$101.4 - $128.73 $1.72 Million - $2.18 Million
-16,953 Reduced 77.1%
5,034 $548,000
Q3 2018

Nov 14, 2018
BUY
$113.81 - $129.46 $780,508 - $887,836
6,858 Added 45.33%
21,987 $2.81 Million
Q2 2018

Aug 14, 2018
BUY
$101.14 - $118.31 $248,197 - $290,332
2,454 Added 19.36%
15,129 $1.71 Million
Q1 2018

May 14, 2018
BUY
$107.21 - $151.94 $80,300 - $113,803
749 Added 6.28%
12,675 $1.42 Million
Q4 2017

Feb 14, 2018
BUY
$118.58 - $151.28 $561,832 - $716,764
4,738 Added 65.92%
11,926 $1.76 Million
Q3 2017

Nov 08, 2017
BUY
$114.6 - $136.81 $823,744 - $983,390
7,188
7,188 $842,000

Others Institutions Holding UTHR

# of Institutions
668
Shares Held
42.8M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.3B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email